Fluorouracil
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Fluorouracil
- Fluorouracil: From Gastric Cancer and Skin Conditions to Rhabdomyosarcoma (Botryoid-Type Embryonal Rhabdomyosarcoma of the Vagina)
Fluorouracil: From Gastric Cancer and Skin Conditions to Rhabdomyosarcoma (Botryoid-Type Embryonal Rhabdomyosarcoma of the Vagina)
One-Sentence Summary
Fluorouracil is an antimetabolite chemotherapy originally used for gastrointestinal cancers (such as gastric, colon and pancreatic cancer) and for skin conditions such as actinic keratosis and superficial basal cell carcinoma. The TxGNN model predicts it may be effective for botryoid-type embryonal rhabdomyosarcoma of the vagina, with a very high score but no clinical trials and no publications specific to this subtype. The prediction therefore rests on the model alone; the closest supporting material is a small set of indirect papers on rhabdomyosarcoma in general.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gastric cancer, colorectal metastasis, pancreatic adenocarcinoma, actinic keratosis, superficial basal cell carcinoma (the Singapore licence records contain no indication text) |
| Predicted New Indication | Botryoid-type embryonal rhabdomyosarcoma of the vagina |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Based on general knowledge, fluorouracil is a thymidylate synthase inhibitor and antimetabolite. It interferes with DNA and RNA synthesis in rapidly dividing cells, which is why it works in fast-growing tumours.
Rhabdomyosarcoma is a fast-growing soft-tissue sarcoma, mostly in children, so a general antimetabolite rationale is plausible. However, standard rhabdomyosarcoma regimens (for example vincristine, actinomycin D and cyclophosphamide) do not centre on fluorouracil. No trials or papers were found for this specific vaginal subtype. The high score should be read as a model-based hypothesis, not as evidence of benefit.
Other rhabdomyosarcoma-related predictions (general rhabdomyosarcoma, parameningeal, bile duct, prostate and liver sarcoma forms) have similar scores and similarly limited evidence. Three sickle cell syndromes also appear in the model's top ten, but they have no supporting data. Fluorouracil's toxicity makes it an unlikely choice for chronic non-malignant conditions.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No publications were retrieved for the vaginal subtype itself. For the closely related broader indication, rhabdomyosarcoma, the following indirect material was found:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3884137 | 1985 | Review | Cancer | Value of adjuvant chemotherapy in childhood sarcomas; no fluorouracil-specific finding confirmed |
| 6277228 | 1981 | Review | Ann Acad Med Singapore | General review of cancers curable with chemotherapy, including childhood rhabdomyosarcoma |
| 42483493 | 2026 | Case report | Case Rep Oncol Med | Adult lingual rhabdomyosarcoma; cisplatin plus 5-fluorouracil was followed by disease progression |
| 3951398 | 1986 | Cohort | Med Pediatr Oncol | Childhood nasopharyngeal carcinoma; likely off-target |
These sources are old, indirect or anecdotal. None shows that fluorouracil contributes benefit in rhabdomyosarcoma, and the one case report describes progression on a fluorouracil-containing regimen.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN05050P | DBL Fluorouracil Injection BP 50mg/mL (Hospira Australia) | Injection | Not recorded |
| SIN09904P | Fluorouracil Injection 50 mg/ml (Pharmachemie BV) | Injection | Not recorded |
| SIN04266P | Verrumal Solution (Almirall Hermal GmbH) | Solution | Not recorded |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (fluoropyrimidine antimetabolite) |
| Myelosuppression Risk | Medium to high for the injectable form; neutropenia, leukopenia and thrombocytopenia are listed among its known risk conditions |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | Complete blood count with differential, liver and renal function, electrolytes; consider DPD deficiency assessment before systemic use |
| Handling Protection | Injectable products must be handled according to cytotoxic drug handling regulations |
Safety Considerations
- Contraindication-related conditions (from the knowledge graph, not from label text): kidney disease, liver disease, gallbladder disease, thrombocytopenia, neutropenia, agranulocytosis, leukopenia, diarrhoeal disease, active peptic ulcer disease, pharyngitis, stomatitis, pyoureter, and dihydropyrimidine dehydrogenase (DPD) deficiency.
- Drug Interactions: 100 interactions were found in total. The highest-rated shown are moderate: metronidazole and tinidazole. Minor interactions include cimetidine and levofloxacin. Many others (for example omeprazole, pantoprazole, metformin, morphine) have an unrated severity.
Package insert warnings and contraindications for the Singapore products were not available; please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score (L5). There are no trials or publications for this subtype, standard rhabdomyosarcoma treatment does not rely on fluorouracil, and the only related case report showed progression. The safety profile, including myelosuppression and DPD-deficiency risk, requires a clear efficacy signal before further investment.
To proceed, the following is needed:
- Subtype-specific preclinical data (for example, cell-line sensitivity of embryonal rhabdomyosarcoma to fluorouracil)
- A systematic literature search for fluorouracil in rhabdomyosarcoma regimens, with full-text verification
- Mechanism-of-action data and the Singapore package insert warnings and contraindications
- Confirmation of the approved indications for the three Singapore licences
- A safety and dosing plan for paediatric patients, including DPD deficiency screening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.